FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Paggiarino Dario A.					2. Issuer Name and Ticker or Trading Symbol EyePoint Pharmaceuticals, Inc. [EYPT]								eck all applic Director Officer	,		10% Ow Other (s	ner
(Last) (First) (Middle) C/O EYEPOINT PHARMACEUTICALS, INC. 480 PLEASANT STREET					3. Date of Earliest Transaction (Month/Day/Year) 06/14/2018								below)	hief Med	lical (below)	
(Street) WATER		1A	02472	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(5	State)	(Zip) ble I - Non-D	erivati		- Curities	- Δα	nuired D	ien	nosed o	of or Rei	neficially	, Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D			Transaction te	ction 2A. Deemed Execution Date,		3. 4. Securities Ac Disposed Of (D) Code (Instr.		ties Acquire	ed (A) or	5. Amour	s For ally (D) ollowing (I) (orm: Direct) or Indirect (Instr. 4) (7. Nature of Indirect Beneficial Ownership (Instr. 4)			
						Code	′	Amount	(A) or (D)	Price	Transacti (Instr. 3 a	ion(s)			,		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	tive Conversion Date Execution Date, Tr ty or Exercise (Month/Day/Year) if any Co		Code (nsaction Derivative E		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisable		kpiration ate	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)			
Restricted Stock Units	(1)	06/14/2018		A		42,600		(2)		(2)	Common Stock	42,600	\$0.00	42,60	00	D	
Stock Option (right to buy)	\$2.04	06/14/2018		A		170,500		(3)	06	5/14/2028	Common Stock	170,500	\$0.00	170,50	00	D	

Explanation of Responses:

- $1. \ Each \ restricted \ stock \ unit \ represents \ a \ contingent \ right \ to \ receive \ one \ share \ of \ the \ Company's \ common \ stock.$
- 2. The restricted stock units will vest in three equal annual installments beginning June 14, 2019. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date.
- 3. The option to purchase will vest and become exercisable in three equal annual installments beginning June 14, 2019.

Remarks:

/s/ John Mercer, Attorney-in-Fact 06/18/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

 $Persons \ who \ respond \ to \ the \ collection \ of \ information \ contained \ in \ this \ form \ are \ not \ required \ to \ respond \ unless \ the \ form \ displays \ a \ currently \ valid \ OMB \ Number.$